University at Buffalo - The State University of New York
Skip to Content
Javier                         Blanco

Javier G. Blanco Clin. Biochem., Ph.D.

Department of Pharmaceutical Sciences


Specialty/Research Focus


Professional Summary:

Research focus is the improvement of cancer chemotherapy by understanding the factors that contribute to interindividual variability in drug response.

Dr. Blanco‘s goal is to perform translational research using a combination of approaches based on a) the analysis of biological samples from selected
populations, and b) the use of informative laboratory models.

A project in Dr. Blanco‘s laboratory is related to the understanding of the factors that govern interindividual variability in the metabolism and disposition of the anthracyclines doxorubicin and daunorubicin. It is possible that specific sequence variations in genes associated with the metabolism and disposition of anthracyclines may impact the risk of cardiotoxicity in some individuals. Our efforts are focused on the discovery and characterization of novel single-nucleotide polymorphisms in a family of genes involved in the metabolism of anthracyclines in liver, heart and different types of tumors (e.g. breast and lung cancer). We are investigating the extent of DNA sequence variation in these selected gene candidates among normal individuals from different ethnic groups. We will study genotype-phenotype correlations by using paired tissue-DNA-RNA samples available from my collaborators from the Pharmacogenetics of Anticancer Agents Research group, and from the Roswell Park Cancer Institute. We will expand our studies to characterize the functional effect of the genetic variants by using different in-vitro and in-vivo models (e.g. cultures of hepatocytes,cardiomyocytes, transgenic mice).

Our findings are being translated into informative case-control epidemiological studies. For example, we are analyzing the distribution of candidate polymorphisms in identically treated patients who have vs. have not developed congestive heart failure (CHF) after anthracycline treatment for childhood cancer. In the future, individualizing the dosing of anthracyclines based on genetic characteristics might minimize the occurrence of adverse effects.

Education and Training:
  • Postdoctoral Research Associate, St. Jude Children‘s Research Hospital (2002)
  • PhD, National University of Cordoba, Argentina, Outstanding (10/10) (1998)
  • Professional Degree, Clinical Biochemistry, National University of Cordoba, Argentina (1993)
  • Professor, State University of New York at Buffalo, School of Pharmacy and Pharmaceutical Sciences (2017-present)
  • Member, Molecular Targets & Experimental Therapeutics Program, Roswell Park Cancer Institute, Buffalo, NY, USA (2003-present)
  • Associate Professor, State University of New York at Buffalo, School of Pharmacy and Pharmaceutical Sciences (2008–2017)
  • Assistant Professor, State University of New York at Buffalo, School of Pharmacy and Pharmaceutical Sciences (2003–2008)
  • Postdoctoral Research Associate, Pharmaceutical Sciences, St Jude Children Research Hospital (1998–2002)
  • Resident, Central laboratory, clinical chemistry, Province of Cordoba Children's Hospital, Argentina (1992–1993)
Awards and Honors:
  • Medal of Honor, Argentine Society of Genetics (SAG) (2017)
  • Top 100 Principal Investigators (2005)
  • Fellow (by competition with peer review evaluation) of the Federal Secretariat of Science and Technology (SECyT), Argentina Project: Study of the effect of Natural Compounds Isolated from Plants on the Catalytic Activity of Steroidogenic Enzymes (1998)
  • Research Fellow. Competitive Research Fellowship with peer review evaluation. Three consecutive renewals (1994 - 1997). Project: Characterization of a Novel Group of Aromatase Inhibitors from Plants of the Northwestern Region of Argentina (1994)

Research Expertise:
  • Professional degree in clinical biochemistry: The recipient of this degree is qualified to practice clinical biochemistry in various clinical settings.
Grants and Sponsored Research:
  • April 2015–May 2019
    Contribution of CBRs and AKRs to the Pharmacodynamics of Anthracycline Drugs
    National Institute of General Medical Sciences
    Role: Principal Investigator
  • April 2017–March 2019
    Epigenetic Regulation of FcRn Expression in Human Lung and its Role in the Disposition of Monoclonal Antibody Drugs
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    Role: Principal Investigator
  • March 2017–February 2019
    Integrating Naltrexone Treatment, Alcoholics Anonymous Facilitation, and the OPRM1 Polymorphism in the Treatment of Alcohol Dependent Outpatients
    Buffalo Clinical and Translational Research Center
    Role: Co-Investigator
  • January 2012–February 2018
    Enabling Access to Cutting-Edge Biomedical and Behavioral Sciences
    National Institutes of Health
    Role: Contributor
  • April 2014–March 2017
    Characterization of Cardiac Mitochondrial DNA in Donors with Down Syndrome
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    Role: Principal Investigator
  • March 2014–January 2017
    Pinpointing Molecular Determinants for the Cardiotoxicity Associated with the Use of Trastuzumab for Breast Cancer Chemotherapy
    The Mae Stone Goode Trust
    Role: Principal Investigator
  • Inhibitory Action of Sesquiterpene Lactones on the Aromatase Activity File Number 337.384. National Institute of Industrial Property. Ministry of Public Service, Argentina (2006)

Journal Articles:
See all (38 more)
  • Ferguson D, Blanco JG. Elucidating the Effect of DNA Methylation on the Regulation of Human Neonatal Fc Receptor (FcRn). ASPET Annual Meeting at Experimental Biology. 2017.
  • Ferguson D, Blanco JG. Identifying MicroRNA Determinants of Neonatal Fc Receptor (FcRn) Expression in Humans. 2016 AAPS National Biotechnology Conference. 2016.
  • Blanco JG. Investigation of the Pharmacogenetic Influences of Carbonyl Reductase on Doxorubicin and Doxorubicinol in Breast Cancer Patients. American Society of Clinical Oncology. 2013.
  • Blanco JG; Bhatia S; Sun C; Landier W; Chen L; Oeffinger K; Hudson M; Neglia J; Ritchey A; Relling M. Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children‘s Oncology Group study. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings. 2010; 28.
  • Sanborn C; Kalabus JL; Jamil R; Blanco JG. Increased carbonyl reductase 1 (CBR1) expression in hearts from donors with Down syndrome. Sixth Annual Celebration of Academic Excellence- University at Buffalo, SUNY. 2010.
  • Gonzalez-Covarrubias VM; Blanco JG. Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. 2008.

Professional Memberships:
  • Argentinean Society of Genetics (SAG) (2016–present)
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) (2014–present)
  • American Association of Clinical Pharmacology (AACP) (2009–present)
  • The Pharmacogenetics Research Network (PharmGKB); Affiliated Member (2007–present)
  • American Association of Pharmaceutical Scientists (AAPS); Member (2005–present)
  • American Association of Colleges of Pharmacy (AACP); Member (2003–2008)
  • The Children‘s Oncology Group (COG); Member (2002–present)
  • American Society of Hematology (ASH); Member (2001–2010)
  • Argentinian Society of Biochemistry and Molecular Biology (SAIB); Member (1994–1998)
  • Society of Biology of Córdoba (Argentina); Member (1994–1998)
  • "Molecular Determinants for Anthracycline-Related Cardiotoxicity in Survivors of Pediatric Cancers" , Center for Childhood Cancer and Blood Disorders, Nationwide Children’s Hospital (2017)
  • "Organizer, Dialogue and Debate Session Stem-Cell Derived Cell Lines: Platforms to Evaluate Drug Metabolism and Transport" 2016 AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists (2016)
  • "Pharmacogenetics: Clinical Implementation and Regulatory Considerations" 1rst National Scientific Congress on Professional Biochemistry, National University of Córdoba, Córdoba Catholic University, and Province of Córdoba Society of Clinical Biochemistry. Córdoba, Argentina (2016)
  • "Pharmacogenomic Determinants Associated to the Cardiotoxicity of Anthracycline Drugs" XVI Latin-American Congress of Genetics, Latin American Society of Genetics, Montevideo, Uruguay (2016)
  • "Post graduate level course in Pharmacogenetics. Module: Cancer Pharmacogenetics" Faculty of Chemistry, University of the Republic, Montevideo, Uruguay (2016)
  • "The Pharmacogenomics of Anthracycline-related Cardiotoxicity in Survivors of Pediatric Cancers" , Roswell Park Cancer Institute, Cancer Genetics Program (2016)
  • "Identification of Pharmacogenetic Determinants in Cardio-Oncology" VI Ibero-American Congress of Pharmaceutical Sciences/XLVII Meeting of the Argentinian Society of Experimental Pharmacology/III South American Congress of Biopharmacy and Pharmacokinetics, Sponsored by the Argentinian Ministry of Science and Technology (RAICES program) (2015)
  • "The Pharmacogenetics of Anthracycline-Based Therapies in Survivors of Pediatric Cancers" , Department of Clinical Biochemistry, Faculty of Chemical Sciences, National University of Córdoba, Argentina (2015)
  • "Pinpointing Molecular Determinants for the Cardiotoxicity Associated to Anticancer Therapies" , Albany College of Pharmacy and Health Sciences (2015)
  • "Pharmacogenetic Insights into Anthracycline-Related Cardiotoxicity" , University of Florida College of Pharmacy (2015)
  • "Basic Notions on Clinical Pharmacogenetics: Recent Developments and Clinical Utility." Barcelo University: special conference, Barceló University, La Rioja, Argentina (2014)
  • "Clinical Pharmacogenetics" Post graduate level course in Clinical Pharmacogenetics. National University of Cordoba, National University of Cordoba (2014)
  • "The Pharmacogenetic Bases of Cardio-oncology." Barcelo University: special conference (2014)
  • "Pharmacogenetics of Late Effects in Survivors of Pediatric Cancers (Farmacogenetica en Sobrevivientes de Canceres Pediatricos)" Post-graduate level course "Molecular Bases of Gene Expression and its Impact in Cell Physiology". Department of Clinical Biochemistry, National University of Córdoba, National University of Córdoba (2012)
  • "Trends in Pharmacogenetics: Defining Clinical Utility (Nociones Básicas de Farmacogenética: Desarrollos Recientes y Utilidad Clínica)" Argentinian Food, Drugs, and Medical Technology Administration (ANMAT), Argentinian Food, Drugs, and Medical Technology Administration (ANMAT) (2012)
  • "Pharmacogenetics of Pediatric Cancers. Genetic Determinants of Efficacy and Late Toxicity (Farmacogenética de Cánceres Pediátricos. Determinantes Genéticos de Eficacia y Toxicidad Tardia)" Argentinian Society of Pediatrics (Catamarca‘s Division) and the Committee for Research and Teaching Development (Catamarca‘s Province Central Children‘s Hospital) (2012)
  • "Novel Risk Factors for Anthracycline-related Cardiomyopathy in Pediatric Cancer Survivors. A Report from the Children's Oncology Group." XII Buffalo Pharmaceutics Symposium, Department of Pharmaceutical Sciences, SoPPS (2010)
  • "Anthracycline-related cardiomyopathy in childhood cancer survivors and associations with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study" Annual Meeting of the American Society of Clinical Oncology, American Society of Clinical Oncology (ASCO) (2010)
  • "Pharmacogenetics of Human CBR1 in Livers from Black and White Donors" Annual Meeting of the American Association of Pharmaceutical Scientists, American Association of Pharmaceutical Scientists (2008)
See all (9 more)
Service Activities:
  • UB's IMPACT proposals: Life Sciences Panel; Reviewer (2017)
  • Center for Integrated Global Biomedical Sciences, University at Buffalo; Member (2016–present)
  • Academic Integrity Committee, University at Buffalo; Member (2015–present)
  • National Institutes of Health: Xenobiotics Nutrients and Disposition Study Section (XNDA); Grant Reviewer (2015)
  • Cardio-Oncology Journal. Editorial Board Member; Editorial Board Member (2015–present)
  • Clinical Implementation Pharmacogenetics Consortium (CIPC); Member (2014–present)
  • Reviewer for a new eCourse sponsored by the AAPS on Translational Sciences. Unit: Novel Methods for Predicting Safety and Efficacy; Reviewer (2014–present)
  • Reviewer, IMPACT proposals: Biomarker, Therapeutic Discovery & Devices; Grant Reviewer (2014–present)
  • Steering Committee Member, AAPS, The Drug Metabolism Focus Group; Member (2014–present)
  • The American Kennel Club. Canine Health Foundation; Grant Reviewer (2013)
  • Member, Graduate Studies Committee, Department of Pharmaceutical Sciences; Member (2013–present)
  • SoPPS Teacher of the Year Award; Reviewed teaching portfolios and made award recommendations Selected the recipient for the 2012 Teacher of the Year award; Member (2012)
  • National Institutes of Health: Xenobiotics Nutrients and Disposition Study Section (XNDA); Grant Reviewer (2012)
  • UB-UZ AIDS International Training and Research Program; Research Advisor for UB-UZ AIDS program.; Member (2012)
  • Director, Pharmaceutical Genetics Laboratory, School of Pharmacy and Pharmaceutical Sciences; Director (2011–present)
  • The Leukemia and Lymphoma Society; Reviewer: Translational Research Program and Quality of Life Initiative. The Leukemia and Lymphoma Society is a premier non for profit organization whose mission is to find cures for hematological cancers.; Reviewer (2011–present)
  • ACPE SoPPS Accreditation 2011 - Curriculum committee; Work with other members to prepare final ACPE report for School's accreditation. Specifically, I was in charge of Curriculum Std 13.; Member (2010)
  • Interviewer-Assistant Vice President for Research; Represented the Department of Pharmaceutical Sciences during interviews. Interviewed applicants for the position of Assistant Vice President of Research; Member (2010)
  • Pharmacogenetics and Personalized Medicine Committe, XII Buffalo Pharmaceutics Symposium; Invited speakers to present at the XII Buffalo Pharmaceutics Symposium. Coordinated arrangements, and moderated discussions; Moderator (2010)
  • 2010 Teacher of the Year Award Committee; Reviewed and discussed 8 teaching porfolios for the 2010 teacher of the year award.; Member (2010)
  • Buffalo Pharmaceutics Symposium; Chair: Pharmacogenetics and Pharmacogenomics section Organization and coordination of the Pharmacogenetics and Pharmacogenomics section; Organizing Committee Member (2010)
  • School of Pharmacy Office of Admissions; To conduct periodical reviews of student applications to the School of Pharmacy and Pharmaceutical Sciences.; Reviewer (2009–present)
  • 2010 Searle Scholar Award Comimttee; Reviewed and discussed applications for the 2010 Searle Award; Member (2009)
  • National Institutes of Health-Special Emphasis Panel: The Pharmacogenomics Research Network (U01/U19); Grant Reviewer (2009)
  • Curriculum Committee; Participates in regular meetings focused on the professional curriculum for the PharmD program.; Member (2008)
  • Graduate Studies Commitee; Participates in regular meetings focused on Departmental Graduate affairs.; Member (2008)
  • Shool's Admissions Committee; Participates in regular meetings focused on the admission process for the School of Pharmacy and Pharmaceutical Sciences.; Member (2008–present)
  • National Institutes of Health-Special Emphasis Panel: The Genes, Environment and Health Initiative” (ZDA1- GXM-A); Grant Reviewer (2008)
  • Tenure and promotion advisory committee; To recommend external and internal candidates for the review of a tenure dossier; Member (2008)
  • Key Adverse Events After Childhood Cancer-ALTE03N1; The Children‘s Oncology Group My group plays a key role in this multi-institutional & collaborative translational research effort. We have identified the first genetic risk factor for anthracycline-related cardiotoxicity among pediatric cancer survivors.; Member (2007)
  • PRED-Pharmacogenetics of Human Reductases; The Pharmacogenetics Research My research group PRED (Pharmacogenetics of Human Reductases) is affiliated to the PharmGKB network. PRED has been making periodical contributions (e.g. curated datasets) to the PharmGKB dat; Faculty Liaison (2007)
  • United States-Israel Binational Science Foundation; Reviewer (2006–present)
  • School of Pharmacy Office of Admissions, Interviewer; Interview applicants to the School‘s PharmD program. Interviews are conducted alone or in combination with another SoPPS colleague.Follows interview guidelines and complete individual rubrics.Enter interview scores and make recommendations (i.e. pass/; Panel Member (2005)
  • Fund for Scientific & Technological Research (FONCyT). Ministry of Education, Science & Technology, Argentina; Grant Reviewer (2003–present)
  • Faculty Advisory Committee; Special advisory committee for a junior faculty member. Critical review of scholarly achievements, funding strategies, and overall plans for tenure and promotion.; Other

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

Contact Information

470 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-4820

Log in to Update Your Profile
"); pageTracker._trackPageview();